GARY A LYONS
CIK 1123343 · President and CEO · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$25.20M
Companies
13
Total Filings
143
Lifetime Open-Market Net
-$24.34M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NBIX | Director | 122,141 | $159.76 | $19.51M | -$23.43M | 57 | 2026-05-29 |
| TVTX | Director | 61,500 | $52.04 | $3.20M | -$917.7K | 8 | 2026-05-21 |
| RIGL | Director | 75,000 | $32.85 | $2.46M | $0 | 16 | 2023-07-12 |
| ELDN | Director | — | $3.57 | — | $0 | 3 | 2023-05-02 |
| Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Director | 18,762 | $2.35 | $44.1K | $0 | 10 | 2022-05-17 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 4 | 2020-09-15 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 34,000 | — | — | $0 | 7 | 2020-05-19 |
| Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Director | 7,828 | — | — | $15.3K | 13 | 2018-05-24 |
| PLUS THERAPEUTICS, INC. (CYTX) Delisted | Director | 28,767 | — | — | $0 | 7 | 2018-02-09 |
| HUMANIGEN, INC (KBIO) Delisted | Director | — | — | — | $0 | 2 | 2015-07-14 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Director | 206,145 | — | — | $0 | 7 | 2011-07-12 |
| FACT | Director | 2,500 | $10.65 | $26.6K | $0 | 3 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | — | — | — | $0 | 2 | 2008-08-15 |
Recent Filings · Page 2 of 15
143 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-23 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | NBIX | Exer (M) | +2,100 | $0 | EDGAR |
| 2024-05-16 | NBIX | Mixed | — | -$1.16M | EDGAR |
| 2024-05-10 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2023-12-27 | NBIX | Sell (S) | −10,000 | -$1.30M | EDGAR |
| 2023-12-05 | NBIX | Mixed | — | -$518.9K | EDGAR |
| 2023-09-14 | NBIX | Mixed | — | -$510.2K | EDGAR |
| 2023-09-06 | NBIX | Mixed | — | -$485.4K | EDGAR |
| 2023-07-12 | RIGL | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-05-19 | NBIX | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.